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Background We aimed to develop dose–response relationships for heart failure (HF) following radiation and anthracyclines in
breast cancer treatment, and to assess HF associations with trastuzumab and endocrine therapies.
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Methods
and results
A case–control study was performed within a cohort of breast cancer survivors treated during 1980–2009. Cases
(n = 102) had HF as first cardiovascular diagnosis and were matched 1:3 on age and date of diagnosis. Individual
cardiac radiation doses were estimated, and anthracycline doses and use of trastuzumab and endocrine therapy were
abstracted from oncology notes. For HF cases who received radiotherapy, the estimated median mean heart dose
(MHD) was 6.8 Gy [interquartile range (IQR) 0.9–13.7]. MHD was not associated with HF risk overall [excess rate
ratio (ERR) = 1%/Gy, 95% confidence interval (CI) −2 to 10]. In patients treated with anthracyclines, exposure of
≥20% of the heart to≥20Gy was associated with a rate ratio of 5.7 (95% CI 1.7–21.7) compared to<10% exposed to
≥20Gy. For cases who received radiotherapy, median cumulative anthracycline dose was 247mg/m2 (IQR 240–319).
A dose-dependent increase was observed after anthracycline without trastuzumab (ERR = 1.5% per mg/m2, 95% CI
0.5–4.1). After anthracycline and trastuzumab, the rate ratio was 34.9 (95% CI 11.1–110.1) compared to no
chemotherapy.
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Conclusions In absence of anthracyclines, breast cancer radiotherapy was not associated with increased HF risk. Strongly elevated
HF risks were observed after treatment with anthracyclines and also after treatment with trastuzumab. The benefits
of these systemic treatments usually exceed the risks of HF, but our results emphasize the need to support ongoing
efforts to evaluate preventative strategies.
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Introduction
Radiotherapy, anthracyclines and trastuzumab are commonly used
treatments for breast cancer (BC) and have all been associated
with an increased heart failure (HF) risk.1–10 For radiotherapy there
is evidence that ischaemic heart disease risk increases linearly
with increasing mean heart dose (MHD).11 Evidence that it can
increase HF risk is, however, conflicting.1–4,10,12–15 This may be due
*Corresponding author. Department of Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel: +31 20 512-2483, Fax: +31
20 512-2322, Email: f.v.leeuwen@nki.nl












. to differences in HF evaluation between the different studies, e.g.
inclusion of only first cardiovascular disease (CVD) diagnoses vs.
also those occurring after diagnoses of other CVDs, differences in
the populations studied, the radiotherapy regimens used, or other
cardiotoxic treatments given. Radiotherapy is known to cause
impaired myocardial function in Hodgkin lymphoma survivors.16,17
However, MHD is usually higher for Hodgkin lymphoma than that
for BC. In a systematic review of MHD from BC radiotherapy
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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during 2003–2013, average MHD was 5.4 Gy (range <0.1–28.6)
in left-sided and 3.3 Gy (range 0.4–21.6) in right-sided BC.18 It
remains unclear if this level of radiation exposure increases HF risk.
For anthracyclines there is strong evidence that HF risk increases
with increasing cumulative dose.19 It usually occurs some years
after treatment.2,13,20–23 Trastuzumab also increases HF risk but,
unlike anthracycline-related HF, it usually occurs whilst patients are
still receiving trastuzumab, and it mostly resolves once treatment
is stopped.7–9
In this study we evaluated associations between radiation MHD
and HF, and between anthracycline dose and HF. We also assessed
HF associations with trastuzumab and for endocrine therapy.
Methods
Cohort population
A nested case–control study was performed within a Dutch cohort
of long-term BC survivors treated during 1970–2009. The cohort
was identified through hospital-based registries at the Netherlands
Cancer Institute, Amsterdam and the Erasmus MC Cancer Institute,
Rotterdam. Details of the data collection procedures for the patient
cohort have been published previously,2,4 and are described in online
supplementary Methods S1.
Cases and controls
Eligibility criteria for cases and controls were: (i) a diagnosis of BC
stage I–IIIa between 1976 and 2009, (ii) age at BC diagnosis ≤65 years,
(iii) no distant metastasis and no diagnosis of CVD that could have
caused HF before cut-off date (defined as date of HF diagnosis for
cases, and for controls as the date of BC plus the time interval
between BC and HF diagnosis for the corresponding case), (iv) no BC
recurrence treated with radiotherapy, and (v) no thoracic radiotherapy
for second malignancies other than primary BC before cut-off date.
(Thoracic) radiotherapy for recurrences or second malignancies was an
exclusion criterion because MHD was not available for these regimens.
Chemotherapy and/or endocrine therapy for a second malignancy or
recurrence were allowed and taken into account in the total cumulative
dose of specific drugs.
To include all cases with left ventricular systolic dysfunction, HF
was defined as either dilated cardiomyopathy or HF with reduced
ejection fraction (HFrEF) with ejection fraction (EF) <50%24 or a
>10% drop from baseline EF (grade 2 according to adaption of the
National Cancer Institute Common Terminology Criteria for Adverse
Events; online supplementary Methods S2). In an attempt to exclude
reversible HF, patients known to have a recovered EF ≤1 year after
the first decrease of EF were excluded. CVDs were ascertained
from medical charts and through questionnaires sent to the general
practitioner of each patient in the cohort. For patients with clinical
signs of HF, cardiologists were sent a questionnaire to confirm or
reject the diagnosis. For each HF case, three controls were selected
from the cohort, matched on age (≤5 years) and date of BC diagnosis
(≤5 years). Individuals who had any CVD diagnosed at grade ≥2 before
the cut-off date were not included as controls.
Eligibility of each individual case was discussed (J.N.J., M.S., G.S.S.,
F.E.v.L.) taking into account all cardiovascular measurements and
information, and blinded as to BC treatment. In total, 342 HF cases



















































































.. on the eligibility criteria (online supplementary Table S1). Cases were
permitted to serve as controls up to the date of HF development, and
patients were allowed to serve as controls for multiple cases. In total,
306 controls were matched to cases, involving 290 unique individuals.
Three patients were selected as both case and control, 11 controls
served for two cases, and one control served for three cases.
Data collection
Detailed treatment information was collected from oncology notes,
including drug names, cumulative anthracycline dose, trastuzumab
administration and type of endocrine therapy. Medical history at BC
included: cardiovascular risk factors (diabetes, hypertension, smoking),
and body mass index (BMI). Radiation charts were photocopied.
Radiotherapy dosimetry
A ‘typical CT-scan’ was used to estimate cardiac doses retrospectively
for each woman in the study (online supplementary Methods S3 and
Table S2). In total, 45 regimens were identified and reconstructed on
the ‘typical CT-scan’. Dose distributions were generated for cobalt,
electron and megavoltage beams using a three-dimensional CT treat-
ment planning system (Varian Eclipse™ version 10.0.39). Dose distri-
butions from orthovoltage fields were generated using manual planning.
The MHD, mean left ventricle dose, and the percent volume of heart
receiving ≥5, ≥10, ≥20, and ≥25Gy (V5 to V25) were estimated for
each woman in the study using the total dose received as recorded from
each individual radiotherapy chart and the dose–volume histogram of
the regimen received.
Statistical analyses
Chemotherapy was categorized into mutually exclusive treatment
groups: no chemotherapy, cyclophosphamide, methotrexate, and
5-fluorouracil-like regimens, anthracycline-based chemotherapy,
anthracyclines plus subsequent trastuzumab, and other type of
chemotherapy/unknown type. Cumulative isotoxic doxorubicin dose
(mg/m2) for patients receiving epirubicin was estimated using a con-
version factor of 0.55, i.e. 50mg/m2 doxorubicin was considered
equivalent to 90mg/m2 epirubicin. Four mutually exclusive treatment
categories were considered for endocrine therapy: no endocrine
therapy, tamoxifen, tamoxifen and aromatase inhibitor, and aromatase
inhibitor only. Endocrine therapy was only considered if it started
≥3 months before HF diagnosis/cut-off date.
Rate ratios (RRs) for HF were estimated using logistic regression
conditional on the matching variables, i.e. age at BC diagnosis (30–39,
40–49, 50–59, 60–65 years), year of BC diagnosis (1976–1979,
1980–1989, 1990–1999, 2000–2009), and follow-up duration (<10,
10–19, 20–30 years). Confidence intervals (CIs) for categorical expo-
sure variables were estimated for each category, including the ref-
erence category, from the amount of information in that category.25
HF is known to have different time dependence, aetiology and prog-
nosis depending on the type of exposure. Therefore, in addition
to analyses considering all the data, HF risk was assessed for each
of the exposure radiotherapy, anthracycline and trastuzumab within
separate categories of the other two exposures. For example, HF
RRs were compared for groups of women with different anthracy-
cline doses, separately for women who received radiotherapy but not
trastuzumab, and for women who did not receive either radiother-
apy or trastuzumab. For radiation and anthracyclines, dose–response
relationships were estimated by modelling HF rate as Km(1 + 𝛽d)
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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where d is MHD/doxorubicin equivalent anthracycline dose for indi-
vidual patients, Km is a constant specific to each matched set, and 𝛽 is
excess rate ratio (ERR, i.e. the proportional increase in HF rate) per
unit increase in dose. Modelled cumulative HF incidences were esti-
mated from the RRs together with the cumulative HF risk for the entire
cohort. Analyses were performed using Stata (version 13.0, StataCorp




In 102 cases of HF, the median age at BC diagnosis was 51 years
(Table 1). Radiotherapy was received by 88/102 (86%) cases and
268/306 (88%) controls. Chemotherapy without trastuzumab was
received by 43% cases and by 36% controls. Trastuzumab was
received by 14% cases and 3% controls, nearly all of whom (21/24)
also received anthracycline-based chemotherapy. Patient charac-
teristics by treatment are provided in online supplementary Table
S3. Median age at HF diagnosis was 62 years, which was 10.9 years
(median) after BC diagnosis. Sixty-two percent of the cases were
diagnosed with congestive HF, 19% with dilated cardiomyopathy,
and 20% with both HF and dilated cardiomyopathy (online sup-
plementary Table S4). Tumor characteristics can be found in online
supplementary Table S5.
All treatments
In women treated with radiotherapy, median MHD was 6.8 Gy for
cases and 3.9 Gy for controls. Considering simultaneously all the
treatment types that patients had received (Table 2, model I), the
HF RRs in MHD categories 2–9 and 10+ Gy were 0.8 (95% CI
0.49–1.3) and 1.2 (95% CI 0.72–1.9), compared to patients
with a MHD of ≤2 Gy. Patients exposed to a low MHD were
chosen as reference category instead of patients not treated with
radiotherapy because this latter group might be a selective patient
group. Patients who received anthracyclines but no trastuzumab
had a 6.9 times increased HF rate (95% CI 3.5–13.6) compared to
patients not treated with chemotherapy. After anthracyclines and
trastuzumab, the HF RR was 34.9 (95% CI 11.1–110.1). Analysis
excluding the six cases (and corresponding controls) treated with
trastuzumab for whom recovery in the first year after HF diagnosis
was unknown, showed a lower RR (17.5, 95% CI 5.0–61.3) for
anthracyclines with trastuzumab vs. no chemotherapy (online sup-
plementary Table S6). HF in women who received anthracyclines
without trastuzumab occurred >10 years after diagnosis of BC in
21/33 cases while, in contrast, all 14 cases of failure who received
trastuzumab occurred within the first 4 years after BC (online
supplementary Table S7). In patients who received endocrine ther-
apy with tamoxifen only, the RRs were not increased compared
with patients who did not receive endocrine therapy but in the
13 patients treated with aromatase inhibitors only, a RR of 4.0
was recorded (95% CI1.0–16.3, P = 0.06). Restricting analyses to
patients without second malignancies did not materially affect any



















































































.. Effect of anthracycline dose
Among patients who were not treated with radiotherapy, the effect
of increasing anthracycline dose could not be assessed due to insuf-
ficient numbers (Table 2, model II). The HF rate increased with
increasing anthracycline dose and, compared with patients who
did not receive anthracyclines, the RR for patients with a median
cumulative anthracycline dose of 240mg/m2 (IQR 221–240) was
3.3 (95% CI 1.5–7.2) while for patients with a median cumula-
tive anthracycline dose of 300mg/m2 (IQR 252–360) the RR was
8.6 (95% CI 4.7–15.6). A linear dose–response relationship was
observed, with HF rate increasing by 1.5% per mg/m2 anthracycline
dose (95% CI 0.5–4.1) (Figure 1). Modelled 10-year cumulative
incidence was 1.4% for patients treated with a cumulative anthracy-
cline dose of ≤240mg/m2 and 3.1% for patients with a cumulative
anthracycline dose of >240mg/m2.
Effect of heart radiation dose
Heart failure rate did not increase significantly with MHD. Com-
pared to 0–1Gy MHD, HF RRs were 0.6 (95% CI 0.31–1.1)
for MHD 2–9Gy and 0.7 (95% CI 0.46–1.2) for ≥10Gy MHD
(Table 2, model III). Similarly, in patients who received radiother-
apy and anthracyclines but not trastuzumab, the HF rate did not
increase significantly with increasing MHD. Compared with a base-
line of 0–1Gy MHD, HF RRs were 1.2 (95% CI 0.55–2.8) for
MHD 2–9Gy and 2.8 (95% CI 0.89–9.0) for ≥10Gy MHD. The
ERR based on a linear dose–response relationship for MHD in the
entire study group was 1%/Gy increase (95% CI −2% to 10%). For
patients treated with anthracyclines, a non-significant increase of
8%/Gy increase in MHD was observed (95% CI −3% to 43%). For
patients not treated with anthracyclines, no risk increase was seen
(ERR = 0%/Gy 95% CI−3% to 8%). As for MHD, there were no sig-
nificant associations between mean left ventricle dose and HF risk
(online supplementary Table S8). A model assessing the joint effects
of MHD and anthracyclines showed that, compared to women with
a MHD<10Gy and no anthracyclines, women with a MHD≥10Gy
and no anthracycline had a HF RR of 1.1 (95%CI 0.59–1.9), women
with a MHD <10Gy and anthracyclines had a RR of 6.3 (95% CI
3.0–13.2) and women with a MHD ≥10Gy and anthracyclines had
a RR of 12.4 (95% CI 4.0–39.2) (Table 2, model IV).
Considering radiation dose–volume parameters in patients
treated with anthracyclines without trastuzumab, there was no
increased HF risk in patients according to increasing volume of the
heart receiving 5 or 10Gy (Table 3). However, in patients of whom
≥20% of the heart was exposed to 20Gy (V20), the HF RR was
5.7 (95%CI 1.7–19.4) relative to women with V20 <10%. Also, in
patients with 10–19% of the heart exposed to 25Gy (V25) and 8
cases with V25 ≥20%, HF RRs were 4.1 (95% CI 1.0–15.9) and 7.8
(95% CI 1.8–34.6), respectively, relative to baseline (V25 <10%).
Cardiac risk factors
There was some evidence that obese women (BMI ≥30 kg/m2) had
an increased HF rate compared to women with a BMI<25 kg/m2
(RR 2.4, 95% CI 1.0–5.4, P = 0.07) and that perimenopausal
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Characteristics of heart failure cases and matched controls
Cases (n = 102) Controls (n = 306) P-value*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age at breast cancer diagnosisa
Median age (years) 51.1 [45.1–55.2] 51.1 [45.5–55.2]
30–39 years 12 (11.8) 36 (11.8)
40–49 years 31 (30.4) 93 (30.4)
50–59 years 48 (47.1) 144 (47.1)
60–65 years 11 (10.8) 33 (10.8)
Year of breast cancer diagnosisa
1976–1979 12 (11.8) 41 (13.4)
1980–1989 26 (25.5) 83 (27.1)
1990–1999 32 (31.4) 85 (27.8)
2000–2009 32 (31.4) 97 (31.7)
Type of surgery
Breast conserving surgery 38 (37.3) 167 (54.6)
Mastectomy 64 (62.8) 139 (45.4) <0.001
Radiotherapy
No 14 (13.7) 38 (12.4)
Yes 88 (86.3) 268 (87.6) 0.75
Chemotherapy
No chemotherapy 44 (43.1) 185 (60.5)
Chemotherapy, no trastuzumab 44 (43.1) 111 (36.3)
Chemotherapy and trastuzumab 14 (13.7) 10 (3.3)
No chemotherapy, trastuzumab 0 (0) 0 (0) <0.001
Endocrine therapy
No 65 (63.7) 241 (78.8)
Yes 37 (36.3) 65 (21.2) 0.002
Age at HF diagnosis/cut-off dateb
Median age (years) 62.1 [53.8–69.2] 62.1 [53.8–69.2]
<40 years 3 (2.9) 10 (3.3)
40–49 years 13 (12.8) 38 (12.4)
50–59 years 24 (23.5) 72 (23.5)
60–69 years 37 (36.3) 111 (36.3)
≥70 years 25 (24.5) 75 (24.5)
Time to HF/cut-off datea
Median time (years) 10.9 [3.5–18.4] 10.9 [3.5–18.4]
<1 year 6 (5.9) 18 (5.9)
1–4 years 22 (21.6) 66 (21.6)
5–9 years 17 (16.7) 51 (16.7)
10–14 years 19 (18.6) 56 (18.3)
15–19 years 18 (17.7) 55 (18.0)
≥20 years 20 (19.6) 60 (19.6)
Values are expressed as n (%), or median [interquartile range].
HF, heart failure; IQR, interquartile range.
aMatching factor for control selection.
bThe variable ‘age at HF diagnosis/cut-off date’ is derived from matching factors ‘age at breast cancer diagnosis’ and ‘time to HF/cut-off date’. Cut-off date was defined as date
of HF diagnosis for cases, and for controls as the date of breast cancer plus the time interval between breast cancer and HF diagnosis for the corresponding case.
*P-value for difference in non-matching variables between cases and controls, calculated using a conditional model (accounting for matching variables).
women had an increased rate compared to premenopausal women
(RR 2.2, 95% CI 1.0–4.8, P = 0.10) (online supplementary Table S9).
No significant associations were found between HF rate and smok-
ing or known co-morbidities.
Discussion
This is the first study to assess the relationships between radiation












.. HF in women treated for early BC. There was no significant
association between MHD and HF rate or between mean left
ventricle dose and HF rate. In contrast, there was a strong,
dose-dependent, relation between HF rate and anthracycline dose.
The rate was increased nearly nine-fold for patients who received
a cumulative dose of >240mg/m2 doxorubicin equivalent. Also,
in patients treated with both anthracyclines and radiotherapy of
whom ≥20% of the heart was exposed to 20Gy (V20), the HF
rate was significantly increased relative to other women whose
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Model I: Model for all treatments
considered simultaneously
Radiotherapy
Median [IQR] mean heart dosea (Gy) 6.8 [0.9–13.7] 3.9 [0.9–13.4]
Mean heart dose 0–1Gy 0.4 [0.2–0.9] 28 (27.5) 96 (31.4) 1.0c 0.53–1.9
Mean heart dose 2–9Gy 4.3 [3.8–6.6] 26 (25.5) 83 (27.1) 0.8 0.49–1.3 0.53
Mean heart dose ≥10Gy 14.6 [13.6–17.0] 33 (32.4) 83( 27.1) 1.2 0.72–1.9 0.74
No radiotherapy 14 (13.7) 38 (12.4) 1.4 0.73–2.8 0.51
Mean heart dose unknownb 1 (0.9) 6 (2.0) – –
Chemotherapy
No chemotherapy 44 (43.1) 185 (60.5) 1.0c 0.60–1.7
CMF-like 9 (8.8) 48 (15.7) 0.7 0.30–1.5 0.35
Anthracyclinese 33 (32.4) 60 (19.6) 6.9 3.5–13.6 <0.001
Anthracyclines and trastuzumabe 14 (13.7) 7 (2.3) 34.9f 11.1–110.1 <0.001
Other type of chemotherapy or type unknown 2 (2.0) 6 (2.0) –g –
Endocrine therapy
No endocrine therapy 65 (63.7) 241 (80.4) 1.0c 0.67–1.5
Tamoxifen 20 (19.6) 41 (11.6) 1.5 0.80–2.8 0.29
Tamoxifen and aromatase inhibitors 8 (7.8) 17 (6.0) 1.6 0.57–4.5 0.42
Aromatase inhibitors 8 (7.8) 5 (1.3) 4.0 1.0–16.3 0.06
Type of endocrine therapy unknown 1 (0.9) 2 (0.7) –g –
Model IIh: Cumulative anthracycline dose
by treatment with radiotherapy and trastuzumabi
No radiotherapy
Median [IQR] cumulative anthracycline dosej (mg/m2) 242 [230–302] 252 [241–302]
Total 14 38
No trastuzumab
0mg/m2 11 (78.6) 33 (86.8) – –
≤240mg/m2 231 [231–231]k 1 (7.1) 0 (0) –g –
>240mg/m2 252 [241–302]k 1 (7.1) 5 (13.2) –g –
With trastuzumab
>240mg/m2 302 [302–302]k 1 (7.1) 0 (0) –g –
Radiotherapy
Median [IQR] cumulative anthracycline dosej (mg/m2) 247 [240–319] 240 [240–300]
Total 88 268
No trastuzumab
0mg/m2 43 (48.9) 203 (75.8) 1.0c 0.48–2.1
≤240mg/m2 240 [221–240]k 9 (10.2) 26 (9.7) 3.3 1.5–7.2 0.02
>240mg/m2 300 [252–360]k 23 (26.1) 29 (10.8) 8.6 4.7–15.6 <0.001
With trastuzumab
≤240mg/m2 240 [240–240]k 13 (14.8) 10 (3.7) 25.3 9.7–65.9 <0.001
Model IIIe: Estimated mean heart dose
by anthracycline and trastuzumab
No anthracyclines or trastuzumab
Median [IQR] mean heart dosea,b (Gy) 3.8 [0.2–14.2] 3.8 [0.4–14.2]
Total 54 236
0–1 Gy 0.4 [0.2–0.9] 9 (16.7) 60 (25.4) 1.0c,d 0.43–2.3
2–9Gy 3.8 [3.8–5.4] 12 (22.2) 64 (27.1) 0.6 0.31–1.1 0.30
≥10Gy 14.7 [14.2–18.0] 21 (38.9) 77 (32.6) 0.7 0.46–1.2 0.57
No radiotherapy 11 (20.4) 33 (14.0) 1.1 0.52–2.2 0.87
Mean heart dose unknownb 1 (1.9) 2 (0.9) –g –
Anthracyclines but not trastuzumab
Median [IQR] mean heart dosea,b (Gy) 6.9 [0.9–12.0] 0.9 [0.2–6.3]
Total 34 60
0–1Gy 0.9 [0.2–0.9] 9 (26.5) 29 (48.3) 1.0c 0.42–2.4
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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2–9Gy 6.4 [4.5–6.9] 13 (38.2) 17 (28.3) 1.2 0.55–2.8 0.70
≥10 Gy 15.2 [12.0–16.9] 10 (29.4) 5 (8.3) 2.8 0.89–9.0 0.15
No radiotherapy 2 (5.9) 5 (8.3) 1.2 0.27–5.6 0.82
Mean heart dose unknownb 0 (0) 4 (6.7) –g –
Trastuzumab
Median [IQR] mean heart dosea,b (Gy) 0.9 [0.2–0.9] 0.9 [0.9–6.4]
Total 14 10
0–1 Gy 10 (71.4) 6 (60.0) – –
2–9Gy 2 (14.3) 3 (30.0) –g –
≥10Gy 1 (7.2) 1 (10.0) –g –
No radiotherapy 1 (7.2) 0 (0) –g –
Model IVl : Joint effects of mean heart dose
and anthracyclines
Mean heart dose <10Gy, no anthracyclines 3.3 [0.4–3.9] 32 (31.4) 160 (52.3) 1.0c 0.66–1.5
Mean heart dose ≥10Gy, no anthracyclines 14.7 [14.2–18.0] 21 (20.6) 77 (25.2) 1.1 0.59–1.9 0.85
Mean heart dose <10Gy, anthracyclines 0.9 [0.4–5.0] 37 (36.3) 57 (18.6) 6.3 3.0–13.2 <0.001
Mean heart dose ≥10Gy, anthracyclines 14.9 [12.0–16.8] 11 (10.8) 6 (2.0) 12.4 4.0–39.2 <0.001
Mean heart dose unknownb 1 (1.0) 6 (2.0) –g – –
CI, confidence interval; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; IQR, interquartile range; RR, rate ratio.
RRs for heart failure were estimated using logistic regression conditional on the matching variables.
aIn patients treated with radiotherapy.
bHeart doses were unknown for seven patients (one case, six controls) because their radiotherapy charts were unavailable.
cReference category. CI for categorical exposure variables were estimated for each category, including the reference category, from the amount of information in that category.
dP for trend across categories 0.48.
eAnthracycline treatment consisted of an epirubicin-containing regimen for 14/48 cases and 16/67 controls, and of a doxorubicin-containing regimen for 34/48 cases and 51/67
controls. Trastuzumab was mostly given in combination with anthracyclines.
fRR for anthracyclines plus trastuzumab vs. anthracyclines without trastuzumab is 5.5 (95% CI 1.9–16.0).
gInsufficient numbers to produce reliable estimates for this category.
hModel additionally included a dichotomous variable for endocrine therapy (no/yes).
iRange cumulative anthracycline dose was 90–612 mg/m2 doxorubicin equivalent, the commonest dose was four times 60mg/m2. Two patients were treated with an
anthracycline for breast cancer and then later retreated with an anthracycline for a recurrence or second malignancy. Cumulative anthracycline range for all other patients was
90–366mg/m2. The commonest regimens were: AC (doxorubicin and cyclophosphamide), FAC (5-fluorouracil, doxorubicin, cyclophosphamide), TAC (docetaxel, doxorubicin,
cyclophosphamide), and FEC (5-fluorouracil, epirubicin, cyclophosphamide).
jIn patients treated with anthracyclines.
kMedian anthracycline dose and IQR in patients treated with and without trastuzumab.
lModel also included dichotomous variables for radiotherapy (no/yes), trastuzumab (no/yes), and endocrine therapy (no/yes).
V20 was <10%, suggesting that anthracycline-related cardiotoxicity
may be exacerbated by irradiating a large volume of the heart
to a high dose. This latter finding is, however, based on only 17
patients, and so needs confirmation in other studies. Although
our study included only 24 patients treated with trastuzumab, a
strongly increased HF risk was observed for patients receiving
trastuzumab compared with those who did not receive it. There
was a borderline significant association between treatment with
aromatase inhibitors and HF rate, based on 13 patients, but no
significant increases associated with other types of endocrine
therapy.
In the Netherlands, as in many countries, national BC guidelines
recommend that women at high BC recurrence risk should be
considered for treatment with anthracycline-based chemotherapy
and, if they are HER2 positive, with 1 year of trastuzumab. Our
results are, therefore, particularly relevant to women at high risk
of recurrence. It is, however, important to note that HF rates in


























.. current study are quite low.26 Therefore, these large proportional
increases do not result in a large absolute increase in HF rates for
BC patients, at least not in the first 10–15 years after treatment.
Although the absolute HF rates in young patients may still be
low, recently published mortality rates27 indicate that HF preceded
by anthracycline-based chemotherapy is a disease with a poor
prognosis that requires early recognition, and studies investigating
(medical) interventions are needed.
The time between BC diagnosis and HF diagnosis was much
shorter in cases treated with trastuzumab than in cases treated
with anthracyclines but not trastuzumab. This difference occurred
despite exclusion of reversible treatment-related HF cases occur-
ring within 1 year of treatment. The short latency between
trastuzumab exposure and development of HF has been reported
in large randomized trials in which trastuzumab-related HF devel-
oped during or a few months after treatment and recovered
within 6 years of stopping trastuzumab in >60% of patients.7,8 It
is likely that the presentation of HF differed according to the
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Excess rate ratio (ERR) in heart failure by cumula-
tive anthracycline dose. The regression line is the best fitting
linear dose–response relationship. This results in an ERR of 1.5%
per mg/m2 [95% confidence interval (CI) 0.5–4.1]. Squares indi-
cate point estimates for dose categories (no anthracycline-based
chemotherapy, ≤240mg/m2 cumulative anthracycline dose, and
>240mg/m2 cumulative anthracycline dose, see Table 2) and are
plotted at the mean cumulative anthracycline dose of each cate-
gory. There was no significant departure from linearity observed.







































. exposure. HF diagnoses in patients treated with trastuzumab may
have been less severe given that patients on trastuzumab undergo
repeated surveillance during treatment, whereas patients treated
with anthracyclines without trastuzumab only undergo (repeated)
echocardiography if they present with symptoms. The absence of
cardiac surveillance in this group possibly resulted in a late HF
diagnosis, since a large prospective echocardiographic monitor-
ing study by Cardinale et al.19 showed that most cardiotoxicity
events occurred within the first year after anthracycline-containing
chemotherapy. Other studies have observed increased HF rates
after anthracyclines13,22,23 and after trastuzumab treatment20,21,28
and have shown these differences in time dependence and presen-
tation. The numbers in the other studies are, however, lower than
in our study.
The radiotherapy results in this nested case–control study dif-
fer somewhat from those reported in our cohort study,2 which
reported increased HF rates after radiotherapy without anthracy-
cline treatment. For the current case–control study more detailed
information was collected on HF diagnosis and recovery, and the
HF definition was stricter. Interestingly, Saiki et al.3 also observed
an increased rate of HF after radiotherapy for BC, which was
restricted to HF with a preserved EF (HFpEF) (odds ratio 5.2 per
log MHD, 95% CI 1.4–19.1) while no increased risk was seen for
HFrEF (odds ratio 1.2 per log MHD, 95% CI 0.22–6.0). Exclu-
sion of cases with HFpEF in the current case–control study may
Table 3 Associations between percentage of heart volume receiving ≥5 to ≥25 Gray (V5 to V25) and heart failure risk
in patients treated with anthracyclines and without trastuzumab
Percentage of heart volume
receiving 5–25Gy (V5 to V25)
Cases (n = 29)a Controls (n = 51)a RR Floating 95% CI P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
V5
Median value [IQR] 35.4% [11.2–67.1] 3.0% [0–43.7]
0–9% 6 (20.7) 28 (54.9) 1.0b 0.31–3.3
10–19% 4 (13.8) 5 (9.8) 1.1 0.29–4.3 0.90
≥20% 19 (65.5) 18 (35.3) 2.7 1.2–6.2 0.11
V10
Median value [IQR] 30.7% [7.0–59.2] 1.7% [0–38.5]
0–9% 10 (34.5) 32 (62.8) 1.0b 0.40–2.5
10–19% 3 (10.3) 4 (7.8) 0.7 0.15–3.6 0.74
≥20% 16 (55.2) 15 (29.4) 2.8 1.1–7.0 0.06
V20
Median value [IQR] 15.0% [3.2–26.0] 1.1% [0–13.8]
0–9% 13 (44.8) 36 (70.6) 1.0b 0.43–2.3
10–19% 4 (13.8) 10 (19.6) 1.4 0.36–5.3 0.65
≥20% 12 (41.4) 5 (9.8) 5.7 1.7–19.4 0.01
V25
Median value [IQR] 11.2% [2.0–20.1] 1.0% [0.1–8.9]
0–9% 14 (48.3) 43 (84.3) 1.0b 0.43–2.3
10–19% 7 (24.1) 5 (9.8) 4.1 1.0–15.9 0.05
≥20% 8 (27.6) 3 (5.9) 7.8 1.8–34.6 0.01
CI, confidence interval; IQR, interquartile range; RR, rate ratio; V5-V25, dose–volume parameters.
aDose–volume estimation was not possible for the three patients treated with anthracyclines and without trastuzumab, all cases, who had been treated with a combination
of orthovoltage and electron/megavoltage radiotherapy, and for the four patients treated with anthracyclines without trastuzumab, all controls, for whom the radiotherapy
charts were unavailable.
bReference category.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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explain why we did not observe a clearly increased HF rate after
radiotherapy.
The increased HF rate observed for aromatase inhibitor use
only is intriguing, but should interpreted with caution as we were
unable to stratify our analyses for menopausal status due to lim-
ited patient numbers (these findings were based on 13 patients).
Women treated with aromatase inhibitors only are generally post-
menopausal and may have, due to age and menopausal status, a
worse cardiovascular risk profile, irrespective of type of endocrine
therapy. However, there was no evidence that menopausal status
was a confounder of the relationship between aromatase inhibitors
and HF (data not shown). A number of studies have suggested
that aromatase inhibitors may increase the HF risk.29,30 Haque
et al.29 studied CVD outcomes in over 13 000 post-menopausal
BC patients and found a higher HF risk in patients treated with
aromatase inhibitors compared to patients treated with tamoxifen
only (hazard ratios 1.1–1.3). The fact that we did not observe
an increased HF rate in patients treated with both aromatase
inhibitors and tamoxifen may be explained by treatment duration;
upfront aromatase inhibitors were generally prescribed for a dura-
tion of 5 years compared to a duration of 2.5 years when combined
with tamoxifen (Dutch treatment guidelines, www.oncoline.nl).
Strengths of our study include comprehensive data collection
from medical files, including detailed treatment information, with
individual cumulative anthracycline dose and estimated individual
patient radiation MHD, mean left ventricle dose, and dose–volume
parameters. HF diagnoses were based on information from both a
general practitioner and a cardiologist. Information on the pres-
ence of cardiovascular risk factors at BC diagnosis was collected.
The strict exclusion criteria that we applied with regard to other
cancer treatments and history of clinically significant CVD elim-
inated their influence on the risk estimates. Exclusion of these
cases, however, also means that it was not possible to assess
the effect of BC treatments on HF rates in patients with a his-
tory of CVD before HF diagnosis. Furthermore, patient numbers
in this study were too small to assess interactions between car-
diotoxic treatment and cardiovascular risk factors or menopausal
status. Another potential limitation is the inaccurate registra-
tion of duration of endocrine treatment in the medical files, and
the incompleteness of detailed cardiac information, such as EF
measurements.
In conclusion, our results show a clear dose-dependent increase
in HF risk after anthracycline-based chemotherapy. In the absence
of anthracycline-based chemotherapy, our data suggest that mod-
ern BC radiotherapy does not increase HF risk. HF risks associ-
ated with high doses to the heart (i.e. MHDs exceeding 10Gy
or large volumes of the heart exposed to ≥20Gy) in patients
receiving anthracycline-based chemotherapy require further stud-
ies. Treatment with trastuzumab increases HF risk within 1–2 years
of treatment and anthracycline-based chemotherapy increases HF
risk in the first 10 years after treatment. Both anthracyclines and
trastuzumab cure many women of their cancers, and the abso-
lute gain for a typical woman selected to receive chemother-
apy is usually >5% reduction in BC mortality risk over the next
10 years. For most women this is likely to substantially exceed



















































































.. the need to support ongoing efforts to evaluate preventative
strategies.
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